Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): call me crazy if I had all the answers but, I have more than most …

August 16, 2018 9:37am

Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths

I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric.

I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds!

Now I’m asking you to commit: http://www.regmedinvestors.com/create-account

Insight is developed from a real-time perspective to determine an equity’s attractiveness as stock pricing changes by the hour … if not the minute!

Every business day, RegMed Investors offers you:

Critical Knowledge Ahead of the Market Open: the pre-open thesis … a prognosis of what could or should happen or might not;

Interpretation, Insight and Translation: An exclusive look at how sector companies are evolving their platforms and trial statuses in an ever-changing market. Our deep-dive reporting of news and issues reflects ever-changing pattern analysis tempered by advance/decline lines as well as current tracking of evolving indexes and indices;

Capital Market Access: A run-down on not just which companies are filing for offerings, but also a complete analysis of their size and warrant coverage, At-the-Market (ATM) facilities, debt vehicles, and the price extended to investors;

Companies to Watch: The “stats”, latest updates, and "What's-the-Price" analysis of “our” universe’s latest news includes the break-down of quarterly (Q) and fiscal year (FY) earnings and never forget the “dogs” of our universe;

Actionable Intelligence: Full breakdowns that highlight the impact of trials, developments, platforms and partnerships.

SUBSCRIBE TO RegMed Investors at http://www.regmedinvestors.com/create-account

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.